REG - e-Therapeutics plc - Senior Management Update

E-TherapeuticsAnnouncement

22/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211122:nRSV0249Ta&default-theme=true

RNS Number : 0249T  e-Therapeutics plc  22 November 2021

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Senior Management Update

 

 

Oxford, UK, 22 November 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a
specialist in computational drug discovery with a focus on developing RNA
interference ("RNAi") therapeutics, regrets to announce that Karl Keegan will
step down from his role as CFO (non-board) to focus in the near term on
extremely difficult family circumstances in Ireland.  This will take
effect from 31 December 2021. The Company is actively looking for a new CFO,
during which time Michael Bretherton, a Non-Executive Director of the Company,
will act as interim CFO.  The Company will update the market accordingly.

Michael has been a director of seven other AIM quoted companies during the
last ten years, including DeepMatter Group Plc, Nanoco Group Plc, Ceres Power
Holdings Plc and Tissue Regenix Group Plc. He has a degree in Economics from
Leeds University and is a member of the Institute of Chartered Accountants in
England and Wales. His early career included working as an accountant and
manager with PriceWaterhouse for seven years in London and the Middle East.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "We are
very saddened that Karl will be leaving e-therapeutics under these
circumstances at the end of the year. We are grateful to Karl for his
contribution to e-therapeutics and wish him the very best in the future."

 

Enquiries:

 e-therapeutics plc                                 Tel: +44 (0)1993 883 125
 Ali Mortazavi, CEO                                 www.etherapeutics.co.uk

 SP Angel Corporate Finance LLP                     Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company integrating computational
power and biology to accelerate the discovery of life-transforming medicines.
The Company has developed and validated a powerful, disease and modality
agnostic computational approach to drug discovery, leveraging its
industry-leading expertise in network biology to fully capture and interrogate
human disease complexity.

 

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful mode of
action elucidation. Novel targets can also be identified, prioritised and
assessed. Harnessing internal target gene discoveries, e-therapeutics is
currently building an in-house pipeline of RNAi based medicines, using its
proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its disease-agnostic computational
drug discovery platform both in house and with partners, including Novo
Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDKCBNABDDDDD